Journal of Shandong University (Health Sciences) ›› 2021, Vol. 59 ›› Issue (11): 8-18.doi: 10.6040/j.issn.1671-7554.0.2021.0193
Previous Articles Next Articles
CHAI Xiaoxue1, YE Hui1, LYU Xinran2, DING Xuchao2, ZHEN Qiulai1, DU Juan3, CAO Lili1,2
CLC Number:
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. [2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in china, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132. [3] Singh D, Attri BK, Gill RK, et al. Review on EGFR inhibitors: critical updates [J]. Mini Rev Med Chem, 2016, 16(14): 1134-1166. [4] Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome [J]. N Engl J Med, 2005, 353(2): 133-144. [5] Barreca A, Lasorsa E, Riera L, et al. Anaplastic lymphoma kinase in human cancer [J]. J Mol Endocrinol, 2011, 47(1): R11-R23. [6] Bhatnagar V, Gormley NJ, Luo L, et al. Fda approval summary: daratumumab for treatment of multiple myeloma after one prior therapy [J]. Oncologist, 2017, 22(11): 1347-1353. [7] Kasamon YL, de Claro RA, Wang Y, et al. FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma [J]. Oncologist, 2017, 22(5): 585-591. [8] Fashoyin-Aje L, Donoghue M, Chen H, et al. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 [J]. Oncologist, 2019, 24(1): 103-109. [9] Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy [J]. Oncologist, 2016, 21(5): 634-642. [10] Herr W, Sturm RA, Clerc RG, et al. The POU domain: a large conserved region in the mammalian pit-1, oct-1, oct-2, and Caenorhabditis elegans unc-86 gene products [J]. Genes Dev, 1988, 2(12A): 1513-1516. [11] Vahava O, Morell R, Lynch ED, et al. Mutation in transcription factor POU4F3 associated with inherited progressive hearing loss in humans [J]. Science, 1998, 279(5358): 1950-1954. [12] Weiss S, Gottfried I, Mayrose I, et al. The DFNA15 deafness mutation affects POU4F3 protein stability, localization, and transcriptional activity [J]. Mol Cell Biol, 2003, 23(22): 7957-7964. [13] Masuda M, Li Y, Pak K, et al. The promoter and multiple enhancers of the POU4F3 gene regulate expression in inner ear hair cells [J]. Mol Neurobiol, 2017, 54(7): 5414-5426. [14] He L, Pang X, Chen P, et al. Mutation in the hair cell specific gene POU4F3 is a common cause for autosomal dominant nonsyndromic hearing loss in Chinese Hans [J]. Neural Plast, 2016, 2016: 9890827. doi: 10.1155/2016/9890827. [15] Freitas ÉL, Oiticica J, Silva AG, et al. Deletion of the entire POU4F3 gene in a familial case of autosomal dominant non-syndromic hearing loss [J]. Eur J Med Genet, 2014, 57(4): 125-128. [16] Sayyad Z, Sirohi K, Radha V, et al. 661W is a retinal ganglion precursor-like cell line in which glaucoma-associated optineurin mutants induce cell death selectively [J]. Sci Rep, 2017, 7(1): 16855. [17] Leonard JH, Cook AL, Van Gele M, et al. Proneural and proneuroendocrine transcription factor expression in cutaneous mechanoreceptor(Merkel)cells and Merkel cell carcinoma [J]. Int J Cancer, 2002, 101(2): 103-110. [18] Chen YC, Huang RL, Huang YK, et al. Methylomics analysis identifies epigenetically silenced genes and implies an activation of β-catenin signaling in cervical cancer [J]. Int J Cancer, 2014, 135(1): 117-127. [19] Kocsis A, Takács T, Jeney C, et al. Performance of a new HPV and biomarker assay in the management of hrHPV positive women: subanalysis of the ongoing multicenter TRACE clinical trial(n>6,000)to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer [J]. Int J Cancer, 2017, 140(5): 1119-1133. [20] Wu X, Rauch TA, Zhong X, et al. CpG island hypermethylation in human astrocytomas [J]. Cancer Res, 2010, 70(7): 2718-2727. [21] 周春燕,药立波.生物化学与分子生物学[M].9版.北京:人民卫生出版社,2018: 405. [22] Morris LG, Chan TA. Therapeutic targeting of tumor suppressor genes [J]. Cancer, 2015, 121(9): 1357-1368. [23] Klein CA. Parallel progression of primary tumours and metastases [J]. Nat Rev Cancer, 2009, 9(4): 302-312. [24] 丁兰,柳志军,令利军,等.虎刺醛对人肝癌细胞HepG2生长抑制、细胞迁移抑制及其机制的研究[J].中国细胞生物学学报, 2013, 35(4): 442-449. DING Lan, LIU Zhijun, LING Lijun, et al. Study of damnacanthal on anti-proliferation, cell migration inhibition and its mechanism in human hepatoma cell HepG2 [J]. Chinese Journal of Cell Biology, 2013, 35(4): 442-449. [25] 黄蕾,滕春莹,雷鹏,等.伪足、有氧糖酵解与肿瘤细胞迁移的研究进展[J].癌变·畸变·突变, 2020, 32(1): 72-75. [26] Chazotte B. Labeling cytoskeletal F-actin with rhodamine phalloidin or fluorescein phalloidin for imaging [J]. Cold Spring Harb Protoc, 2010, 2010(5): pdb.prot4947. doi: 10.1101/pdb.prot4947. |
[1] | ZHANG Zhenwei, LI Jia, CHEN Keming. IGF2BP2/m6A/ITGA5 signal axis regulates the proliferation and migration of renal clear cells [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 74-84. |
[2] | CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30-37. |
[3] | ZHENG Haotian, WANG Guanghui, ZHAO Xiaogang, WANG Yadong, ZENG Yukai, DU Jiajun. A prognostic risk model for LKB1 mutant lung adenocarcinoma based on aberrant DNA methylation sites [J]. Journal of Shandong University (Health Sciences), 2022, 60(3): 51-58. |
[4] | SUN Qingjie, ZHANG Yisha, GUAN Shanghui, FENG Zhihui. Effects of valproic acid on the survival and tumor recurrence of 134 patients with glioma treated with radiotherapy [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 80-85. |
[5] | KONG Xue, LI Juan, DUAN Weili, SHI Shuang, LI Peilong, DU Lutao, MAO Haiting, WANG Chuanxin. Effects of lncRNA AC012073.1 on the migration and invasion of human breast cancer cells and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 70-78. |
[6] | XUE Yuan, LIN Xueyan, XU Ge, TIAN Yongjie. Expression of hypoxia-inducible factor-1α in the serum of patients with endometriosis and its effect on epithelial mesenchymal transition of eutopic endometrial stromal cells [J]. Journal of Shandong University (Health Sciences), 2021, 59(2): 41-47. |
[7] | YANG Jia, ZHANG Man, CHEN Kaiming, CAO Xi. Mechanism of miR-146a accelerating macrophage migration induced arteriosclerosis via TLR4/MyD88 pathway [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 1-7. |
[8] | PANG Zhaofei, LIU Yong, ZHAO Xiaogang, YAN Tao, CHEN Xiaowei, DU Jiajun. Construction of a stemness-based scoring model predicting the efficacy of immunotherapy in lung adenocarcinoma based on public databases [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 19-28. |
[9] | SUN Yifeng, GAO Yu, LIANG Yongyuan, GAO Yang. Expression of CPLX2 and its in vitro effects on the proliferation migration and invasion of hepatocellular carcinoma cells [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 34-39. |
[10] | LI Ning, LI Juan, XIE Yan, LI Peilong, WANG Yunshan, DU Lutao, WANG Chuanxin. Expression of LncRNA AL109955.1 in 80 cases of colorectal cancer and its effect on cell proliferation, migration and invasion [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 38-46. |
[11] | MA Qingyuan, PU Peidong, HAN Fei, WANG Chao, ZHU Zhoujun, WANG Weishan, SHI Chenhui. Effect of miR-27b-3p regulating SMAD1 on osteosarcoma cell proliferation, migration and invasion [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 32-37. |
[12] | YANG Xiuting, LIU Qigong, ZUO Ping, LIU Zhengxiang, ZUO Houjuan. Effect of CD151-MUT mutation on migration of lung adenocarcinoma cell line A549 and its mechanism [J]. Journal of Shandong University (Health Sciences), 2020, 58(3): 81-86. |
[13] | SHI Li, MA Jing, ZHAO Xiwa, GUAN Yingxia, ZHAO Lianmei, SHAN Baoen. Expression and function of miR-25-3p in endometrial cancer [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 86-91. |
[14] | HONG Jiageng, NIE Yangyang, SU Guoqiang. Effects of propofol on proliferation, migration and expressions of Wnt1 and β-catenin in colon cancer cells [J]. Journal of Shandong University (Health Sciences), 2020, 58(11): 53-58. |
[15] | LUO Mengying, WU Bei, WANG Ye, LUO Heng, CAO Yu. Effect of ar-turmerone on poliferation, migration and invasion of cervical squamous cancer cell line SiHa [J]. Journal of Shandong University (Health Sciences), 2019, 57(6): 68-74. |
|